Christopher Nanson, MD
Orthopaedic Surgery · Tigard, ORNPI 1386717882
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $57,231 of the $73,420 with a category attached, or 77.9%. Nextstep Arthropedix, LLC accounts for 82.1% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $62,640 and has fallen 89.4% since, to $6,620 in 2025. Among orthopaedic surgery clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 146 payments — averaging $502.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nextstep Arthropedix, LLC$60K
- Zimmer Biomet$5K
- Stryker$4K
- Medacta USA, Inc.$2K
- Ortho Development Corporation$1K
- Heraeus Medical, LLC.$351
- plus $697 from 16 others
What the payments were for
- Royalty or licence$57,23178%
- Speaking & faculty fees$1,2002%
- Travel & lodging$8,68412%
- Food & beverage$6,3069%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nextstep Arthropedix, LLC | 5 | $60,274 |
| Zimmer Biomet | 31 | $5,311 |
| Stryker | 43 | $3,867 |
| Medacta USA, Inc. | 17 | $1,520 |
| Ortho Development Corporation | 5 | $1,400 |
| Heraeus Medical, LLC. | 8 | $351 |
| Pacira Pharmaceuticals Incorporated | 8 | $161 |
| Bioventus LLC | 6 | $114 |
| Pacira Therapeutics, Inc. | 5 | $74 |
| Smith+Nephew | 3 | $53 |
| Johnson & Johnson(2 entities) | 3 | $46 |
| FX Shoulder Solutions, Inc | 1 | $43 |
| Orthalign Inc | 1 | $35 |
| Avanos Medical | 2 | $28 |
| Baxter Healthcare | 1 | $23 |
| Next Science LLC | 1 | $21 |
| Heron Therapeutics, Inc. | 1 | $19 |
| Abbott | 1 | $18 |
| Biocomposites Inc | 1 | $18 |
| Si-bone, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iNSitu Hip System$60,136
- MAKO$2,602
- Persona$1,500
- Balanced Knee System$1,312
- ROSA$1,159
- GMK SPHERE$797
- SPHERIKA$331
- TRIATHLON$292
- PALACOS$217
How this compares
$73,420 in reported general payments places this provider in the 95th percentile of 228 orthopaedic surgery providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine-PrilocaineLidocaine/Prilocaine | 14 | $2,514 |
| Oxycodone Hcl | 73 | $488 |
| Cephalexin | 30 | $56 |
| Meloxicam | 12 | $29 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Tigard
- Brian PuskasTigard$11K
- Adam HeisingerTigard$10K
- Mark WagnerTigard$10K
- Patrick DenardMedford$11.5M
- James BallardOregon City$2.4M
- Steven MadeyLake Oswego$1.2M
- Daniel FitzpatrickEugene$481K
- Michelle WelbornPortland$364K
- Elizabeth LiebermanPortland$353K
- Jonathan SalesPortland$303K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.